Bot Chart, page-9938

It's starting to look like a repeat of the run-up we had to the September anticipated approval date. For more than 4 months, the SP sat between 5 and 6c until February. Then 6 month's out from the anticipated approval, the SP began it's climb up to 21c (or more than 320% from its low only 6 months earlier).

Here we are now, 6-8 months out from approval (and as well known, approval that is now only required concerning labelling and instruction-for-use changes, not the science of the drug itself) and again we see the SP start to move north as we head towards approval. This time of course, it's off a base of 12c, which is conveniently where institutional support for the stock was last demonstrated in July this year when $12.5m was raised, without batting an eyelid.

Throw in a couple of announcements along the way, e.g. meeting with the FDA, lodging the resubmission, quarterly sales figures from Kaken, royalties paid to BOT for Japan sales, etc, and we may see it start to approach the Price Target of 31c recommended by Euroz Hartley's immediately following September's Complete Response Letter: